

60/694628

FILE 'HOME' ENTERED AT 18:00:47 ON 15 OCT 2006

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
2.94	2.94

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 18:08:59 ON 15 OCT 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 18:08:59 ON 15 OCT 2006

FILE 'CAPLUS' ENTERED AT 18:08:59 ON 15 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 18:08:59 ON 15 OCT 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 18:08:59 ON 15 OCT 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s dithiomethyl?

L1 200 DITHIOMETHYL?

=> s l1 and hydrocarbyl

L2 5 L1 AND HYDROCARBYL

=> s l2 and biopolymer?

L3 0 L2 AND BIOPOLYMER?

=> s l2 and oligo?

L4 0 L2 AND OLIGO?

=> s l1 and label?

L5 20 L1 AND LABEL?

=> s l5 and alkyl?

4 FILES SEARCHED...

L6 19 L5 AND ALKYL?

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 19 DUP REM L6 (0 DUPLICATES REMOVED)

=> d l7 bib abs 1-19

L7 ANSWER 1 OF 19 USPATFULL on STN

AN 2006:150972 USPATFULL

TI Anti-integrin immunoconjugates, methods and uses

IN Chen, Qiming, Collegeville, PA, UNITED STATES

Trikha, Mohit, San Mateo, CA, UNITED STATES

Lutz, Robert J., Wayland, MA, UNITED STATES

Steeves, Rita M., Stoneham, MA, UNITED STATES

Amphlett, Godfrey, Cambridge, MA, UNITED STATES

PI US 2006127407 A1 20060615

AI US 2005-290249 A1 20051130 (11)

PRAI US 2004-634445P 20041209 (60)

DT Utility

FS APPLICATION

LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW
BRUNSWICK, NJ, 08933-7003, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2566

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 19 USPATFULL on STN
AN 2006:86115 USPATFULL
TI Compounds and methods to inhibit or augment an inflammatory response
IN Grainger, David J., Cambridge, UNITED KINGDOM
Tatalick, Lauren Marie, Redmond, WA, UNITED STATES
Kanaly, Suzanne T., Seattle, WA, UNITED STATES
PA Cambridge University Technical Services Ltd. (non-U.S. corporation)
PI US 2006073114 A1 20060406
AI US 2002-241375 A1 20020911 (10)
RLI Continuation of Ser. No. US 1998-150813, filed on 11 Sep 1998, PENDING
Continuation-in-part of Ser. No. US 1997-927939, filed on 11 Sep 1997,
GRANTED, Pat. No. US 6989435
DT Utility
FS APPLICATION
LREP SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, 1600 TCF TOWER, 121 SOUTH EIGHT
STREET, MINNEAPOLIS, MN, 55402, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1-51
DRWN 23 Drawing Page(s)
LN.CNT 7392

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 19 USPATFULL on STN
AN 2006:46495 USPATFULL
TI Drug delivery system for hydrophobic drugs
IN Boch, Ronald Erwin, North Vancouver, CANADA
Singh, Dev Mitra Ranji, Surrey, CANADA
Karmadi, Iman, Vancouver, CANADA
PI US 2006039965 A1 20060223
AI US 2005-254400 A1 20051020 (11)
RLI Continuation of Ser. No. US 2001-833406, filed on 11 Apr 2001, GRANTED,
Pat. No. US 6984395
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 12531 HIGH BLUFF DRIVE, SUITE 100, SAN DIEGO,
CA, 92130-2040, US
CLMN Number of Claims: 34

ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1968

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favor the production of small aggregates for improved filter sterilization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 19 USPATFULL on STN

AN 2006:162126 USPATFULL

TI Compounds and methods to inhibit or augment an inflammatory response

IN Grainger, David J., Duxford, UNITED KINGDOM

Tatalick, Lauren Marie, Redmond, WA, UNITED STATES

Kanally, Suzanne T., Seattle, WA, UNITED STATES

PA Cambridge University Technical Services, Ltd., Cambridge, UNITED KINGDOM
(non-U.S. corporation)

PI US 7067117 B1 20060627

AI US 1998-150813 19980911 (9)

RLI Continuation-in-part of Ser. No. US 1997-927939, filed on 11 Sep 1997,
PENDING

DT Utility

FS GRANTED

EXNAM Primary Examiner: Murphy, Joseph

LREP Schwegman, Lundberg, Woessner & Kluth, P.A.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 25 Drawing Figure(s); 23 Drawing Page(s)

LN.CNT 7861

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 19 USPATFULL on STN

AN 2005:215531 USPATFULL

TI Immuno-adjuvant PDT treatment of metastatic tumors

IN Curry, Patrick Mark, Vancouver, CANADA

Richter, Anna M., Vancouver, CANADA

Levy, Julia G., Vancouver, CANADA

Hunt, David W.C., White Rock, CANADA

PI US 2005187207 A1 20050825

AI US 2004-985582 A1 20041109 (10)

RLI Continuation of Ser. No. US 2001-756687, filed on 9 Jan 2001, ABANDONED

Continuation-in-part of Ser. No. US 2000-556833, filed on 21 Apr 2000,
PENDING

PRAI US 1999-130519P 19990423 (60)

DT Utility

FS APPLICATION

LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO,
CA, 92130-2332, US

CLMN Number of Claims: 18

ECL Exemplary Claim: 1-27

DRWN 4 Drawing Page(s)

LN.CNT 2636

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with

immuno-adjuvants to destroy metastatic tumor cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 19 USPATFULL on STN
AN 2004:280944 USPATFULL
TI Renal-selective biphenylalkyl 1H-substituted-1, 2, 4- triazole
angiotensin I I antagonists for treatment of hypertension
IN Reitz, David B., Chesterfield, MO, UNITED STATES
Manning, Robert E., St. Louis, MO, UNITED STATES
PA G.D. Searle & Co.,, Chicago, IL (U.S. corporation)
PI US 2004220245 A1 20041104
AI US 2004-852711 A1 20040524 (10)
RLI Continuation of Ser. No. US 2002-326942, filed on 19 Dec 2002, ABANDONED
Continuation of Ser. No. US 2000-634668, filed on 8 Aug 2000, ABANDONED
Continuation of Ser. No. US 1999-382330, filed on 24 Aug 1999, ABANDONED
Continuation of Ser. No. US 1998-160560, filed on 24 Sep 1998, ABANDONED
Continuation of Ser. No. US 1997-788865, filed on 23 Jan 1997, ABANDONED
Continuation of Ser. No. US 1994-236803, filed on 2 May 1994, GRANTED,
Pat. No. US 5436088 Continuation-in-part of Ser. No. US 1992-949804,
filed on 7 Dec 1992, ABANDONED Continuation-in-part of Ser. No. US
1990-574314, filed on 28 Aug 1990, GRANTED, Pat. No. US 5217985
DT Utility
FS APPLICATION
LREP J. Timothy Keane, PHARMACIA CORPORATION of Pfizer Inc., Corporate Patent
Department, P. O. Box 1027, Chesterfield, MO, 63006
CLMN Number of Claims: 108
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 9432

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Renal-selective compounds are described which, in one embodiment, are
prodrugs preferentially converted in the kidney to compounds capable of
blocking angiotensin II (AII) receptors. These prodrugs are conjugates
formed from two components, namely, a first component provided by an AII
antagonist compound and a second component which is capable of being
cleaved from the first component when both components are chemically
linked within the conjugate. The two components are chemically linked by
a bond which is cleaved selectively in the kidney, for example, by an
enzyme. The liberated AII antagonist compound is then available to block
AII receptors within the kidney. Conjugates of particular interest are
glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole
compounds, of which N-acetylglutamic acid, 5-[[4'-[(3,5-dibutyl-1H-1,2,4-
triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]]carbonylhydrazide, (shown
below) is an example: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 19 USPATFULL on STN
AN 2004:159185 USPATFULL
TI Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin
II antagonists for treatment of hypertension
IN Reitz, David B., Chesterfield, MO, UNITED STATES
Manning, Robert E., St. Louis, MO, UNITED STATES
PA G.D. Searle & Co., Chicago, IL (U.S. corporation)
PI US 2004121989 A1 20040624
AI US 2002-326942 A1 20021219 (10)
RLI Continuation of Ser. No. US 2000-634668, filed on 8 Aug 2000, ABANDONED
Continuation of Ser. No. US 1999-382330, filed on 24 Aug 1999, ABANDONED
Continuation of Ser. No. US 1998-160560, filed on 24 Sep 1998, ABANDONED
Continuation of Ser. No. US 1997-788865, filed on 23 Jan 1997, ABANDONED
Continuation of Ser. No. US 1994-236803, filed on 2 May 1994, GRANTED,
Pat. No. US 5436088 Continuation-in-part of Ser. No. US 1992-949804,
filed on 7 Dec 1992, ABANDONED Continuation-in-part of Ser. No. US

1990-574314, filed on 28 Aug 1990, GRANTED, Pat. No. US 5217985
 DT Utility
 FS APPLICATION
 LREP Pharmacia Corporation, Corporate Patent Department, P.O. Box 5110,
 Chicago, IL, 60680
 CLMN Number of Claims: 108
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Page(s)
 LN.CNT 9388

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



AB Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:717645 CAPLUS
 DN 139:245912
 TI Preparation of 10-(dithiomethylene)acridan derivatives for
 generating chemiluminescence with a peroxidase
 IN Akhavan-Tafti, Hashem; De Silva, Renuka; Xie, Wenhua
 PA Lumigen, Inc., USA
 SO U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 29,222.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003170771	A1	20030911	US 2002-205050	20020725
	US 6858733	B2	20050222		
	US 2003170762	A1	20030911	US 2001-29222	20011220
	US 6872828	B2	20050329		
	WO 2003053934	A1	20030703	WO 2002-US37611	20021218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002352881	A1	20030709	AU 2002-352881	20021218
	CN 1492857	A	20040428	CN 2002-805225	20021218
	EP 1456176	A1	20040915	EP 2002-789841	20021218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005514396	T2	20050519	JP 2003-554650	20021218
	US 2004176599	A1	20040909	US 2004-468257	20040415
	US 2005158815	A1	20050721	US 2005-72457	20050304

PRAI	US 2001-29222	A2	20011220
	US 2002-205050	A	20020725
	WO 2002-US37611	W	20021218
	US 2004-468257	A2	20040415
OS	MARPAT 139:245912		
GI			



AB Title compds. I [wherein R1 and R2 = independently alkyl, aryl, arylalkyl, etc.; or R1 and R2 are joined together by a substituted (hetero)alkylene to form a ring; R3 = (un)substituted (hetero) alkyl, aryl, or aralkyl; R4-R11 = independently = H, Cl, OMe, etc.] were prepared I generate chemiluminescence rapidly by reaction with a peroxidase enzyme and a peroxide and are thus useful in assays employing enzyme-labeled specific binding pairs. Thus, acridan II was prepared via conversion of N-phenylacridan to 9,10-dihydro-10-phenyl-9-acridinecarbodithioic acid Me ester using LDA and MeI in THF and subsequent treatment of the dithio ester with LDA and MeI in THF to form II. The prepared acridan derivs. were tested for enhancement of chemiluminescence in a protocol involving reaction of horseradish peroxidase, peroxide, and EDTA.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 19 USPATFULL on STN

AN 2003:127674 USPATFULL

TI Photodynamic therapy of occult age-related macular degeneration

IN Strong, H. Andrew, North Vancouver, CANADA

Azab, Mohammad, West Vancouver, CANADA

Hao, Yong, Vancouver, CANADA

Koester, John Miller, Duluth, GA, UNITED STATES

Reaves, Troy Albert, JR., Alpharetta, GA, UNITED STATES

PI US 2003087889 A1 20030508

AI US 2002-72272 A1 20020206 (10)

PRAI US 2001-266940P 20010206 (60)

DT Utility

FS APPLICATION

LREP Kawai Lau, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 1727

AB The invention relates to the selection and treatment of subjects afflicted with occult choroidal neovascular lesions, including subjects with age-related macular degeneration, by use of photo dynamic therapy (PDT).

L7 ANSWER 10 OF 19 USPATFULL on STN

AN 2002:280616 USPATFULL

TI Drug delivery system for hydrophobic drugs
IN Boch, Ronald Erwin, Vancouver, CANADA
Singh, Dev Mitra Ranji, Surrey, CANADA
Karmadi, Iman, Vancouver, CANADA
PI US 2002156062 A1 20021024
US 6984395 B2 20060110
AI US 2001-833406 A1 20010411 (9)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO,
CA, 92130-2332
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1930

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 19 USPATFULL on STN
AN 2002:106274 USPATFULL
TI 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
IN Watanabe, Kyoichi A., Stone Mountain, GA, UNITED STATES
Pai, S. Balakrishna, Chamblee, GA, UNITED STATES
PI US 2002055483 A1 20020509
US 7094770 B2 20060822
AI US 2001-834596 A1 20010413 (9)
PRAI US 2000-197068P 20000413 (60)
US 2000-202663P 20000508 (60)
DT Utility
FS APPLICATION
LREP TROUTMAN SANDERS LLP, BANK OF AMERICA PLAZA, SUITE 5200, 600 PEACHTREE STREET, NE, ATLANTA, GA, 30308-2216
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4961

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a composition for and a method of treating hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection or a proliferative disorder in a patient using an effective amount of a compound selected from the group consisting of formulas [I]- [IV] below and mixtures of two or more thereof: ##STR1##

wherein the substituents are as defined herein. Pharmaceutical compositions comprising these compounds in combination with other HBV, HCV, or HDV agents is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 19 USPATFULL on STN
AN 2002:37316 USPATFULL
TI Immuno-adjuvant PDT treatment of metastatic tumors
IN Curry, Patrick Mark, Vancouver, CANADA
Richter, Anna M., Vancouver, CANADA

Levy, Julia G., Vancouver, CANADA
Hunt, David W.C., White Rock, CANADA
PI US 2002022032 A1 20020221
AI US 2001-756687 A1 20010109 (9)
RLI Continuation-in-part of Ser. No. US 2000-556833, filed on 21 Apr 2000,
PENDING
PRAI US 1999-130519P 19990423 (60)
DT Utility
FS APPLICATION
LREP MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO,
CA, 92130-2332
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 2765
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Immuno-adjuvant photodynamic therapy to treat and prevent metastatic
cancer is effected using photosensitizers in combination with
immuno-adjuvants to destroy metastatic tumor cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 19 USPATFULL on STN
AN 2001:160987 USPATFULL
TI PHOSPHONOOXYMETHYL ETHERS OF TAXANE DERIVATIVES
IN GOLIK, JERZY, SOUTHTON, CT, United States
VYAS, DOLATRAI, MADISON, CT, United States
WRIGHT, JOHN J., GUILFORD, CT, United States
WONG, HENRY, DURHAM, CT, United States
KADOW, JOHN F., WALLINGFORD, CT, United States
THOTTATHIL, JOHN K., ROBBINSVILLE, NJ, United States
LI, WEN-SEN, MARLBORO, NJ, United States
KAPLAN, MURRAY A., SYRACUSE, NY, United States
PERRONE, ROBERT K., LIVERPOOL, NY, United States
WITTMAN, MARK D., CHESHIRE, CT, United States
PI US 2001023255 A1 20010920
US 6455575 B2 20020924
AI US 1997-870794 A1 19970606 (8)
RLI Continuation of Ser. No. US 1995-427502, filed on 24 Apr 1995, ABANDONED
Division of Ser. No. US 1994-245119, filed on 17 May 1994, ABANDONED
Continuation-in-part of Ser. No. US 1993-154840, filed on 24 Nov 1993,
ABANDONED Continuation-in-part of Ser. No. US 1993-108015, filed on 17
Aug 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-996455,
filed on 24 Dec 1992, ABANDONED
DT Utility
FS APPLICATION
LREP DAVID M MORSE, PATENT COUNSEL WALLINGFORD, BRISTOL MYERS SQUIBB COMPANY
DEPT 851, PO BOX 5100, WALLINGFORD, CT, 064927660
CLMN Number of Claims: 95
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns antitumor compounds. More particularly,
the invention provides novel taxane derivatives, pharmaceutical
compositions thereof, and their use as antitumor agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 19 USPATFULL on STN
AN 97:59234 USPATFULL
TI Phosphonooxymethyl ethers of taxane derivatives
IN Golik, Jerzy, Southington, CT, United States
Vyas, Dolatrai, Madison, CT, United States

Wright, John J., Guilford, CT, United States
Wong, Henry, Durham, CT, United States
Kadow, John F., Wallingford, CT, United States
Thottathil, John K., Robbinsville, NJ, United States
Li, Wen-Sen, Marlboro, NJ, United States
Kaplan, Murray A., Syracuse, NY, United States
Perrone, Robert K., Liverpool, NY, United States
Wittman, Mark D., Cheshire, CT, United States

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

PI US 5646176 19970708

AI US 1995-445360 19950519 (8)

RLI Continuation of Ser. No. US 1994-245119, filed on 17 May 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-154840, filed on 24 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-108015, filed on 17 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-996445, filed on 24 Dec 1992, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Trinh, Ba K.

LREP Yang, Mollie M., Han, William T., DuBoff, Samuel J.

CLMN Number of Claims: 43

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4991

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 19 USPATFULL on STN

AN 94:7708 USPATFULL

TI Cycloheptimidazolone compounds as angiotensin II antagonists for control of hypertension

IN Bovy, Philippe R., St. Louis, MO, United States

O'Neal, Joan M., Glendale, MO, United States

Chamberlain, Timothy S., Chesterfield, MO, United States

Collins, Joe T., Ballwin, MO, United States

PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)

PI US 5281615 19940125

AI US 1992-840471 19920224 (7)

DCD 20090414

RLI Continuation of Ser. No. US 1989-449700, filed on 11 Dec 1989, now patented, Pat. No. US 5104891

DT Utility

FS Granted

EXNAM Primary Examiner: Dentz, Bernard

LREP Keane, J. Timothy

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2237

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of cycloheptimidazolone compounds is described as angiotensin II antagonists for use in control of hypertension. Compounds of particular interest are those of the formula ##STR1## wherein each of R.sup.1 and R.sup.2 is independently selected from hydrido, alkyl, halo, alkanoyl, carboxyl, alkoxycarbonyl, phenyl, haloalkyl, alkoxyalkyl, formyl, cyano, alkoxy, phenoxy, phenylthio, alkylthio; wherein R.sup.3 is alkyl, alkenyl, alkynyl, hydroxyalkyl and alkoxyalkyl; wherein each of R.sup.5 through R.sup.13 is independently

selected from hydrido, alkyl, haloalkyl, halo, nitro, cyano, hydroxy, alkoxy, alkylthio, aryl, aryloxy, arylthio, and acidic groups such as carboxylic acid, with the proviso that at least one of R.sup.9 through R.sup.13 substituents is an acidic group; or a pharmaceutically-acceptable ester, amide or salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 19 USPATFULL on STN
AN 93:78921 USPATFULL
TI Imidazolidyl macrolides having immunosuppressive activity
IN Goulet, Mark, Westfield, NJ, United States
Sinclair, Peter J., Highland Park, NJ, United States
Wong, Frederick, Glen Ridge, NJ, United States
Wyvratt, Matthew J., Mountainside, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5247076 19930921
AI US 1992-921181 19920804 (7)
RLI Continuation-in-part of Ser. No. US 1991-756633, filed on 9 Sep 1991,
now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Bond, Robert T.
LREP Caruso, Charles M., Thies, J. Eric
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Imidazolidyl macrolides of the general structural Formula I: ##STR1##
have been prepared from suitable precursors by alkylation
and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These
macrolide immunosuppressants are useful in a mammalian host for the
treatment of autoimmune diseases, infectious diseases the prevention of
rejection of foreign organ transplants and/or related afflictions,
diseases and illnesses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 19 USPATFULL on STN
AN 93:46431 USPATFULL
TI Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin
II antagonists for treatment of hypertension
IN Reitz, David B., Chesterfield, MO, United States
Manning, Robert E., St. Louis, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5217985 19930608
AI US 1990-574314 19900828 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Miltenberger,
Lenora A.
LREP Keane, J. Timothy, Matukaitis, Paul D.
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 5861

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Renal-selective compounds are described which, in one embodiment, are
prodrugs preferentially converted in the kidney to compounds capable of
blocking angiotensin II (AII) receptors. These prodrugs are conjugates
formed from two components, namely, a first component provided by an AII
antagonist compound and a second component which is capable of being
cleaved from the first component when both components are chemically

linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole compounds, of which N-acetylglutamic acid, 5-[[4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]]carbonylhydrazide, (shown below) is an example: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 19 USPATFULL on STN
AN 92:29708 USPATFULL
TI Cycloheptimidazolone compounds as angiotensin II antagonists for control of hypertension
IN Bovy, Philippe R., St. Louis, MO, United States
O'Neal, Joan M., Glendale, MO, United States
Chamberlain, Timothy S., Chesterfield, MO, United States
Collins, Joe T., Ballwin, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5104891 19920414
AI US 1989-449700 19891211 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann
LREP Keane, J. Timothy, Matukaitis, Paul D.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2820

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of cycloheptimidazolone compounds is described as angiotensin II antagonists for use in control of hypertension. Compounds of particular interest are those of the formula ##STR1## wherein each of R.sup.1 and R.sup.2 is independently selected from hydrido, alkyl, halo, alkanoyl, carboxyl, alkoxycarbonyl, phenyl, haloalkyl, alkoxyalkyl, formyl, cyano, alkoxy, phenoxy, phenylthio, alkylthio; wherein R.sup.3 is alkyl, alkenyl, alkynyl, hydroxyalkyl and alkoxyalkyl; wherein each of R.sup.5 through R.sup.13 is independently selected from hydrido, alkyl, haloalkyl, halo, nitro, cyano, hydroxy, alkoxy, alkylthio, aryl, aryloxy, arylthio, and acidic groups such as carboxylic acid, with the proviso that at least one of R.sup.9 through R.sup.13 substituents is an acidic group; or a pharmaceutically-acceptable ester, amide or salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 19 USPATFULL on STN
AN 92:23204 USPATFULL
TI 1H-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
IN Reitz, David B., Chesterfield, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5098920 19920324
AI US 1990-519380 19900504 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Springer, David B.
LREP Keane, J. Timothy, Matukaitis, Paul D.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5460

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of 1H-substituted-1,2,4-triazole compounds is described for use in treatment of cardiovascular disorders. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein R.sup.1 is selected from hydroxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl, 1,1-dimethoxy-butyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo, difluoro-methyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-di-fluorobutyl and 1,1-difluoropentyl; wherein R.sup.2 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neo-pentyl; wherein each of R.sup.3 through R.sup.11 is hydrido with the provision that at least one of R.sup.5 and R.sup.9 must be selected from COOH, SH, PO.sub.3 H.sub.2, SO.sub.3 H, CONHNH.sub.2, CONHNHSO.sub.2 CF.sub.3, OH, ##STR2## wherein each of R.sup.40 and R.sup.41 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 12 bib abs 1-5

L2 ANSWER 1 OF 5 USPATFULL on STN
AN 93:46431 USPATFULL
TI Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin
II antagonists for treatment of hypertension
IN Reitz, David B., Chesterfield, MO, United States
Manning, Robert E., St. Louis, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5217985 19930608
AI US 1990-574314 19900828 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Miltenberger,
Lenora A.
LREP Keane, J. Timothy, Matukaitis, Paul D.
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 5861
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Renal-selective compounds are described which, in one embodiment, are
prodrugs preferentially converted in the kidney to compounds capable of
blocking angiotensin II (AII) receptors. These prodrugs are conjugates
formed from two components, namely, a first component provided by an AII
antagonist compound and a second component which is capable of being
cleaved from the first component when both components are chemically
linked within the conjugate. The two components are chemically linked by
a bond which is cleaved selectively in the kidney, for example, by an
enzyme. The liberated AII antagonist compound is then available to block
AII receptors within the kidney. Conjugates of particular interest are
glutamyl derivatives of biphenylmethyl 1H-substituted-1,2,4-triazole
compounds, of which N-acetylglutamic acid, 5-[[4'-[(3,5-dibutyl-1H-1,2,4-
triazol-1-yl)methyl][1,1'-biphenyl]-2-yl]]carbonylhydrazide, (shown
below) is an example: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 5 USPATFULL on STN
AN 92:23204 USPATFULL
TI 1H-substituted-1,2,4-triazole compounds and methods of use thereof for
treatment of cardiovascular disorders
IN Reitz, David B., Chesterfield, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5098920 19920324
AI US 1990-519380 19900504 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Springer, David B.
LREP Keane, J. Timothy, Matukaitis, Paul D.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5460
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A class of 1H-substituted-1,2,4-triazole compounds is described for use
in treatment of cardiovascular disorders. Compounds of particular
interest are angiotensin II antagonists of the formula ##STR1## wherein
R.sup.1 is selected from hydroxy, methyl, ethyl, n-propyl, isopropyl,
n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl,
neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl,
1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl, 1,1-dimethoxypropyl,
1,1-dimethoxy-butyl, 1,1-dimethoxypentyl, hydroxyalkyl, halo,

difluoro-methyl, 1,1-difluoroethyl, 1,1-difluoropropyl, 1,1-di-fluorobutyl and 1,1-difluoropentyl; wherein R.sup.2 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl and neo-pentyl; wherein each of R.sup.3 through R.sup.11 is hydrido with the provision that at least one of R.sup.5 and R.sup.9 must be selected from COOH, SH, PO.sub.3 H.sub.2, SO.sub.3 H, CONHNH.sub.2, CONHNHSO.sub.2 CF.sub.3, OH, ##STR2## wherein each of R.sup.40 and R.sup.41 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 5 USPATFULL on STN
AN 76:24848 USPATFULL
TI Pesticidal N-hydrocarbylsulfenyl-N-alkyl-N'-arylformamidines
IN Rizzo, Victor L., Almena Township, Van Buren County, MI, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 3954997 19760504
AI US 1974-537270 19741230 (5)
RLI Division of Ser. No. US 1973-366999, filed on 1 Jun 1973, now patented, Pat. No. US 3887619
DT Utility
FS Granted
EXNAM Primary Examiner: Schenkman, Leonard
LREP Killinger, John J., Saliwanchik, Roman
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel pesticidal N-hydrocarbylsulfenyl derivatives of N-alkyl-N'-aryl formamidines are disclosed with novel compositions thereof and methods of their use in controlling invertebrate pests, particularly insects and acarina. Certain of the novel compounds are particularly effective miticides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 5 USPATFULL on STN
AN 75:29321 USPATFULL
TI N-hydrocarbylsulfenyl-N-alkyl-N'-arylformamidines
IN Rizzo, Victor L., Almena, MI, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 3887619 19750603
AI US 1973-366999 19730601 (5)
DT Utility
FS Granted
EXNAM Primary Examiner: Zitver, Leon; Assistant Examiner: Schwartz, Gerald A.
LREP Saliwanchik, Roman, Killinger, John J.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 934

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel pesticidal N-hydrocarbylsulfenyl derivatives of N-alkyl-N'-aryl formamidines are disclosed with novel compositions thereof and methods of their use in controlling invertebrate pests, particularly insects and acarina. Certain of the novel compounds are particularly effective miticides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 5 USPATFULL on STN
AN 72:48981 USPATFULL
TI CATALYTIC OXIDATION OF POLYMETHYLSTILBENE COMPOUNDS
IN Weinstein, Benjamin, Morganville, NJ, United States
Rein, Burton Maxwell, East Brunswick, NJ, United States
PA Mobil Oil Corporation, United States (U.S. corporation)
PI US 3694500 19720926
AI US 1969-861451 19690926 (4)
DT Utility
FS Granted
EXNAM Primary Examiner: Weinberger, Lorraine A.; Assistant Examiner:
Weissberg, R. S.
LREP Hayes; Oswald G., Gaboriault; Andrew L., Snowden; James F.
CLMN Number of Claims: 4
DRWN No Drawings
LN.CNT 457

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The catalytic oxidation of a polymethyl-substituted stilbene compound with molecular oxygen in a liquid reaction mixture containing a lower fatty acid (e.g., acetic acid) as the reaction solvent, a soluble cobalt compound as the oxidation catalyst and preferably a reaction activator (e.g., methyl ethyl ketone, etc.) produces a benzene polycarboxylic acid as exemplified by the oxidation of 4,4'-dimethylstilbene to terephthalic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:00:47 ON 15 OCT 2006)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 18:08:59 ON 15 OCT 2006

L1 200 S DITHIOMETHYL?
L2 5 S L1 AND HYDROCARBYL
L3 0 S L2 AND BIOPOLYMER?
L4 0 S L2 AND OLIGO?
L5 20 S L1 AND LABEL?
L6 19 S L5 AND ALKYL?
L7 19 DUP REM L6 (0 DUPLICATES REMOVED)

=> s hydrocarbyldithiomethyl?

L8 9 HYDROCARBYLDITHIOMETHYL?

=> dup rem l8

PROCESSING COMPLETED FOR L8

L9 7 DUP REM L8 (2 DUPLICATES REMOVED)

=> d 19 bib abs 1-7

L9 ANSWER 1 OF 7 USPATFULL on STN
AN 2004:227340 USPATFULL
TI Compounds for protecting hydroxyls and methods for their use
IN Kwiatkowski, Marek, Uppsala, SWEDEN
PA Quiatech AB, a Swedish corporation (non-U.S. corporation)
PI US 2004175726 A1 20040909
AI US 2003-694628 A1 20031027 (10)
RLI Continuation of Ser. No. US 2001-952719, filed on 12 Sep 2001, GRANTED, Pat. No. US 6639088 Division of Ser. No. US 1999-412171, filed on 5 Oct 1999, GRANTED, Pat. No. US 6309836
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON P.C., 3300 DAIN RAUSCHER PLAZA, 60 SOUTH SIXTH STREET, MINNEAPOLIS, MN, 55402
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1099
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A hydrocarbyldithiomethyl-modified compound of the Formula:

R.sup.1--O--CH.sub.2--S--S--R.sup.2

or a salt thereof wherein R.sup.1 is an organic molecule and R.sup.2 is a hydrocarbyl is useful for protecting and/or blocking hydroxyl groups in organic molecules such as nucleotides. The hydrocarbyldithiomethyl-modified compounds can also be used for chemically synthesizing oligonucleotides and for sequencing nucleic acid compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 7 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
AN 2003:559412 BIOSIS
DN PREV200300562246
TI Compounds for protecting hydroxyls and methods for their use.
AU Kwiatkowski, Marek [Inventor, Reprint Author]
CS Uppsala, Sweden
ASSIGNEE: Quiatech AB, Sweden
PI US 6639088 20031028

SO Official Gazette of the United States Patent and Trademark Office Patents,
(Oct 28 2003) Vol. 1275, No. 4. <http://www.uspto.gov/web/menu/patdata.html>
. e-file.

ISSN: 0098-1133 (ISSN print).

DT Patent

LA English

ED Entered STN: 26 Nov 2003

Last Updated on STN: 26 Nov 2003

AB A hydrocarbyldithiomethyl-modified compound of the Formula: R1
--O--CH2 --S--S--R2 or a salt thereof wherein R1 is an organic molecule
and R2 is a hydrocarbyl is useful for protecting and/or blocking hydroxyl
groups in organic molecules such as nucleotides. The
hydrocarbyldithiomethyl-modified compounds can also be used for
chemically synthesizing oligonucleotides and for sequencing nucleic acid
compounds.

L9 ANSWER 3 OF 7 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2003-679532 [64] WPIDS

DNC C2003-185669

TI Composition useful for purifying organic chemicals e.g. chemically
synthesized oligonucleotides, comprises oligonucleotides and a separation
medium.

DC B05

IN KWIATKOWSKI, M

PA (KWIA-I) KWIATKOWSKI M

CYC 103

PI WO 2003066651 A1 20030814 (200364)* EN 16

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
ZM ZW

US 2003153741 A1 20030814 (200364)

AU 2003206331 A1 20030902 (200425)

EP 1511758 A1 20050309 (200518) EN

R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
MC MK NL PT RO SE SI SK TR

JP 2005517018 W 20050609 (200538) 23

CN 1628123 A 20050615 (200563)

ADT WO 2003066651 A1 WO 2003-SE208 20030207; US 2003153741 A1 US 2002-71585

20020208; AU 2003206331 A1 AU 2003-206331 20030207; EP 1511758 A1 EP

2003-703623 20030207, WO 2003-SE208 20030207; JP 2005517018 W JP

2003-566022 20030207, WO 2003-SE208 20030207; CN 1628123 A CN 2003-803410
20030207

FDT AU 2003206331 A1 Based on WO 2003066651; EP 1511758 A1 Based on WO

2003066651; JP 2005517018 W Based on WO 2003066651

PRAI US 2002-71585 20020208

AN 2003-679532 [64] WPIDS

AB WO2003066651 A UPAB: 20031006

NOVELTY - A composition comprises several oligonucleotides (I) and a
separation medium.

Each (I) comprises a first separation tag attached to a first end of
(I) and a second separation tag attached to a second end of (I).

The cleavage of the first or second separation tags yields an
oligonucleotide having a 3'-hydroxyl moiety.

(I) adhere to the separation medium.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the
separation of oligonucleotides comprising:

(a) contacting several oligonucleotides containing at least one
bifunctional oligonucleotide and at least one non-bifunctional
oligonucleotide with a separation medium under conditions for adhering at
least one bifunctional oligonucleotide to the separation medium; and

(b) selectively eluting at least one non-bifunctional oligonucleotide.

The bifunctional oligonucleotide comprises a first separation tag attached to a first end of the at least one bifunctional oligonucleotide and a second separation tag attached to a second end of the at least one bifunctional oligonucleotide.

The cleavage of the first or second separation tags yields an oligonucleotide having a 3'-hydroxyl moiety.

USE - The composition is used for purifying chemically synthesized oligonucleotides (claimed); and for purifying organic chemicals.

ADVANTAGE - The composition separates the complete oligonucleotides of the desired length and containing both separation tags.

Dwg.0/3

L9 ANSWER 4 OF 7 USPATFULL on STN
AN 2003:220450 USPATFULL
TI Methods for separating oligonucleotides
IN Kwiatkowski, Marek, Uppsala, SWEDEN
PI US 2003153741 A1 20030814
AI US 2002-71585 A1 20020208 (10)
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON P.C., 3300 DAIN RAUSCHER PLAZA, 60 SOUTH SIXTH STREET, MINNEAPOLIS, MN, 55402
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 884

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for separating oligonucleotides are described. The oligonucleotides to be separated include separation tags attached to each end of the oligonucleotides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 7 USPATFULL on STN
AN 2002:27115 USPATFULL
TI Compounds for protecting hydroxyls and methods for their use
IN Kwiatkowski, Marek, Uppsala, SWEDEN
PI US 2002015961 A1 20020207
US 6639088 B2 20031028
AI US 2001-952719 A1 20010912 (9)
RLI Division of Ser. No. US 1999-412171, filed on 5 Oct 1999, GRANTED, Pat. No. US 6309836
DT Utility
FS APPLICATION
LREP CHAD A. HANSON, PH.D., Fish & Richardson P.C., P.A., Suite 3300, 60 South Sixth Street, Minneapolis, MN, 55402
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hydrocarbyldithiomethyl-modified compound of the Formula:

R.sup.1--O--CH.sub.2--S--S--R.sup.2

or a salt thereof wherein R.sup.1 is an organic molecule and R.sup.2 is a hydrocarbyl is useful for protecting and/or blocking hydroxyl groups in organic molecules such as nucleotides. The hydrocarbyldithiomethyl-modified compounds can also be used for chemically synthesizing oligonucleotides and for sequencing nucleic acid compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 7 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
DUPLICATE 1
AN 2002:7017 BIOSIS
DN PREV200200007017
TI Compounds for protecting hydroxyls and methods for their use.
AU Kwiatkowski, Marek [Inventor, Reprint author]
CS Lovsangeravagen 17, SE-756 52, Uppsala, Sweden
PI US 6309836 20011030
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Oct. 30, 2001) Vol. 1251, No. 5. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 28 Dec 2001
Last Updated on STN: 25 Feb 2002
AB A hydrocarbyldithiomethyl-modified compound of the Formula: R1
--O--CH2 --S--S--R2 or a salt thereof wherein R1 is an organic molecule
and R2 is a hydrocarbyl is useful for protecting and/or blocking hydroxyl
groups in organic molecules such as nucleotides. The
hydrocarbyldithiomethyl-modified compounds can also be used for
chemically synthesizing oligonucleotides and for sequencing nucleic acid
compounds.

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
AN 2001:265430 CAPLUS
DN 134:266522
TI Preparation of nucleosides as synthons of oligodeoxyribonucleotides using
hydroxyl protecting groups
IN Kwiatkowski, Marek
PA Quiatech AB, Swed.
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025247	A1	20010412	WO 2000-SE1929	20001005
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				
	YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6309836	B1	20011030	US 1999-412171	19991005
	CA 2386221	AA	20010412	CA 2000-2386221	20001005
	EP 1218391	A1	20020703	EP 2000-970403	20001005
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003511386	T2	20030325	JP 2001-528191	20001005
	US 2002015961	A1	20020207	US 2001-952719	20010912
	US 6639088	B2	20031028		
	US 2004175726	A1	20040909	US 2003-694628	20031027
PRAI	US 1999-412171	A	19991005		
	WO 2000-SE1929	W	20001005		
	US 2001-952719	A1	20010912		
OS	MARPAT 134:266522				
AB	A hydrocarbyldithiomethyl-modified compound of the Formula R1-O--CH2-S-S-R2, or a salt thereof wherein R1 is an organic mol. and R2 is a				

hydrocarbyl, is useful for protecting and/or blocking hydroxyl groups in organic mols. such as nucleotides. The hydrocarbyldithiomethyl-modified compds. can also be used for chemical synthesizing oligonucleotides and for sequencing nucleic acid compds. Thus, 5'-O-FMOC-3'-O-(4-methylphenylthiosulfonatemethyl)thymidine was prepared as synthons of oligodeoxyribonucleotides.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>